Skip to content Skip to footer
Subscribe Now
Viewpoints_Jason Lerner
VIEWPOINTS

Transcending Epilepsy Care: Jason Lerner from Biohaven in an Enlightening Dialogue Exchange with PharmaShots

Shots:  Epilepsy affects around 1.5 million people in the US and 50 million globally. With approximately 40% of epilepsy patients being drug-resistant, there is an urgent need for innovative therapies  Today, at PharmaShots we have Dr. Jason Lerner from Biohaven shedding light on BHV-7000, an investigational anti-seizure treatment and selective activator of potassium channels in…
November 6, 2024

Read more

Key Biosimilars Events of October 2024
INSIGHTS+

Key Biosimilars Events of October 2024

Shots:       Biosimilars are developed to be highly similar versions of approved biologics in terms of safety, purity, and potency        Biosimilars are expected to be a cost-effective alternative to the high-priced branded biologics, offering significant and much-needed cost savings to both payers and patients        The major highlights were the US FDA’s approval of Dong-A ST’s Imuldosa…
November 5, 2024

Read more

Viewpoints_Fred Aslan
VIEWPOINTS

Enhancing Care with NK Cell Therapy: Fred Aslan from Artiva Biotherapeutics in Conversation with PharmaShots

Shots:  Immune reset in oncology has been observed with approved autologous CAR-T products. A recent study published in Nature demonstrated B-cell reconstitution and immune reset in systemic lupus erythematosus (SLE) patients treated with a CD19 autologous CAR-T, showcasing promising potential in autoimmune diseases  Today, at PharmaShots, we have Fred Aslan shedding light on Artiva's AlloNK,…
November 4, 2024

Read more

Prescription Drugs Top 20 2024
TOP 20

Top 20 Prescription Drugs of 2024

Shots: Driven by an endless pursuit of innovation, the biopharma industry is working tirelessly to bring new-age therapies to patients with serious health conditions and lifestyle-influenced diseases In 2023, the global prescription drug market size was valued at $1162.61B and is anticipated to reach $2151.63B by 2032 registering a CAGR of 7.1 %. Keytruda ranks 1st…
October 31, 2024

Read more

Viewpoints_Adityo Prakash
VIEWPOINTS

AI in Drug Discovery: Adityo Prakash from Verseon in an Illuminating Dialogue Exchange with PharmaShots

Shots:  AI is widely used in drug discovery and clinical research to find innovative cures for several debilitating conditions with unmet healthcare needs  Most of the AI architecture employs deep learning that requires extensive training data sets to produce reliable predictive models  Today, at PharmaShots, we have Adityo Prakash, CEO of Verseon, addressing the challenges…
October 30, 2024

Read more

Viewpoints_Mina Makar
VIEWPOINTS

AstraZeneca at ERA’24: Mina Makar in a Stimulating Conversation with PharmaShots

Shots:  Recently, AstraZeneca presented findings from the real-world IMPACT CKD study, which evaluated the multifaceted impact of CKD on patients, healthcare systems, and broader society, projecting future implications through 2032.  The study emphasizes the importance of mitigating the economic burden on healthcare by implementing early, targeted screening, diagnosis, and treatment for CKD.  In collaboration with…
October 28, 2024

Read more

Viewpoints_Baldo Scassellati Sforzolini
VIEWPOINTS

Unlocking Approval: Baldo Scassellati Sforzolini from Galderma in a Stimulating Dialogue Exchange with PharmaShots

Shots:  Galderma’s Nemluvio (nemolizumab) was recently approved by the US FDA for the treatment of adults with prurigo nodularis, following positive Phase III results from the OLYMPIA study.  Today at PharmaShots, we have Baldo Scassellati Sforzolini, Global Head of Research & Development at Galderma, to discuss the study’s design and the potential of Nemluvio in…
October 23, 2024

Read more

Load more